A multicenter study of clinical usefulness of flow-mediated vasodilation A

Conditions

Patients with coronary artery disease

Yamaji T, Yusoff FM, Kishimoto S, Kajikawa M, Yoshimura K, Nakano Y, Goto C, Harada T, Mizobuchi A, Tanigawa S, Maruhashi T, Higashi Y.

2023-12-256 citations

10.1016/j.jacl.2023.12.006

Inconvenient relationship of haemoglobin A1c level with endothelial function in type 2 diabetes in a cross-sectional study

Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yuji Takaeko, Masato Kajikawa et al. (16 authors)

BMJ Open2021-06-016 citations

10.1136/bmjopen-2020-045415

Lower triglyceride levels are associated with better endothelial function.

Takaeko Y, Maruhashi T, Kajikawa M, Kishimoto S, Yamaji T, Harada T, Hashimoto Y, Han Y, Kihara Y, Chayama K, Goto C, Yusoff FM, Yoshimura K, Nakashima A, Higashi Y.

2021-04-2914 citations

10.1016/j.jacl.2021.04.004

Pre-impaired fasting glucose state is a risk factor for endothelial dysfunction: Flow-mediated Dilation Japan (FMD-J) study

Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yuji Takaeko, Masato Kajikawa et al. (15 authors)

BMJ Open Diabetes Research & Care2020-10-0119 citations

10.1136/bmjdrc-2020-001610

Relationship between high-density lipoprotein cholesterol levels and endothelial function in women: a cross-sectional study

Yuji Takaeko, Shogo Matsui, Masato Kajikawa, Tatsuya Maruhashi, Takayuki Yamaji et al. (17 authors)

BMJ Open2020-07-019 citations

10.1136/bmjopen-2020-038121

Diagnostic Criteria of Flow‐Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin‐Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery

Tatsuya Maruhashi, Masato Kajikawa, Shinji Kishimoto, Haruki Hashimoto, Yuji Takaeko et al. (39 authors)

Journal of the American Heart Association2020-01-08122 citations

10.1161/jaha.119.013915

Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD-J (Flow-Mediated Dilation Japan) Study A.

Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Aibara Y, Mohamad Yusoff F, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y.

2018-07-1288 citations

10.1161/jaha.118.008588

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Enrolled patients are those with diagnosis of coronary artery disease, with the number of diseased arteries determined by either coronary angiography, cardiac nuclear scintigraphy, or coronary CT and who have been under regular follow-up at any of the participating centers for at least 6 months.

Exclusion criteria

Exclusion criteria: A history of coronary bypass surgery; severe valvular heart disease; arrhythmia which requires treatment (ie, atrial fibrillation, atrial flutter, permanent pacemaker implantation or frequent ventricular premature beats); severe chronic heart failure (a New York Heart Association level of greater than Level III); malignancy; current receiving treatment with steroids, nonsteroidal anti-inflammatory drugs or immunosuppressive drugs; a serum creatinine level greater than 2.5 mg/dL; a history of stroke or aortic disease, and serious liver disease.

Design outcomes

Primary

Measure	Time frame
The present study has 2 primary composite endpoints; the first was coronary artery restenosis or de novo coronary artery stenosis as confirmed by diagnostic imaging (ie, coronary angiography, coronary computed tomography, or radioisotope scintigraphy) either with or without the clinical symptoms of fatal or nonfatal myocardial infarction; second was stroke or heart failure and sudden death.	—

Secondary

Measure	Time frame
The secondary endpoints include each of the 2 primary endpoints plus recurrence of angina pectoris without confirmation by diagnostic imaging (ie, confirmed by symptom self-reports only), newly diagnosed aortic diseases (aneurysm or dissection) as confirmed by diagnostic imaging, newly diagnosed peripheral arterial disease as confirmed by an ABI of less than 0.9, and malignancy or death.	—

Countries

Japan

Contacts

Public ContactYukihito Higashi

Research Institute for Radiation Biology and Medicine Department of Cardiovascular Regeneration and Medicine

yhigashi@hiroshima-u.ac.jp082-257-5831

Outcome results